EX-32.1 5 sum-ex321_20250331x10q.htm EX-32.1

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERS AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Summit Therapeutics Inc. (the “Company”) for the quarter ended March 31, 2025, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 1, 2025
By:			/s/ Robert W. Duggan
			Name:			Robert W. Duggan
			Title:			Co-Chief Executive Officer and Chairman of the Board of Directors
						(Principal Executive Officer)
Date: May 1, 2025
By:			/s/ Mahkam Zanganeh
			Name:			Dr. Mahkam Zanganeh
			Title:			Co-Chief Executive Officer, President and Director
						(Principal Executive Officer)
Date: May 1, 2025
By:			/s/ Manmeet S. Soni
			Name:			Manmeet S. Soni
			Title:			Chief Operating Officer, Chief Financial Officer and Director
						(Principal Financial Officer)